Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Citius Oncology ( (CTOR) ) has shared an announcement.
On April 29, 2026, Citius Oncology announced it had shipped the first international order of LYMPHIR to Europe via a regional distribution partner, expanding access to the CTCL therapy outside the U.S. under Named Patient Programs in select markets. The move marks a strategic extension of the drug’s reach beyond its December 2025 U.S. commercial launch, even as LYMPHIR lacks European marketing authorization.
The company said the European rollout complements early U.S. adoption, where it is advancing formulary access, payer coverage and physician engagement across academic and community oncology centers. By leveraging Named Patient Programs and its existing intellectual property protections, Citius aims to strengthen LYMPHIR’s commercial footprint and competitive position in targeted oncology while focusing on disciplined, targeted market entry.
The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
The score is primarily held down by weak financial performance (no revenue, widening losses, and worsening cash burn) and limited valuation support (negative P/E, no dividend). Technicals are only modestly supportive with mixed trend signals, while corporate events are balanced between encouraging product momentum and elevated Nasdaq delisting risk.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Citius Oncology, Inc. is an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc., specializing in the development and commercialization of targeted cancer therapies. Its lead product, LYMPHIR (denileukin diftitox-cxdl), is an FDA-approved treatment for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, addressing an underserved and growing market that management estimates currently exceeds $400 million.
Average Trading Volume: 252,074
Technical Sentiment Signal: Sell
Current Market Cap: $77.11M
See more data about CTOR stock on TipRanks’ Stock Analysis page.